Your browser is no longer supported. Please, upgrade your browser.
Settings
HTBX Heat Biologics, Inc. daily Stock Chart
HTBX [NASD]
Heat Biologics, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own3.62% Shs Outstand34.17M Perf Week-6.25%
Market Cap15.38M Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float32.63M Perf Month-16.53%
Income-21.60M PEG- EPS next Q-0.16 Inst Own9.80% Short Float1.87% Perf Quarter-15.90%
Sales3.10M P/S4.96 EPS this Y82.60% Inst Trans-6.84% Short Ratio1.84 Perf Half Y-36.58%
Book/sh0.49 P/B0.92 EPS next Y26.70% ROA-68.70% Target Price6.88 Perf Year-66.17%
Cash/sh0.44 P/C1.03 EPS next 5Y- ROE-90.20% 52W Range0.35 - 1.80 Perf YTD-54.08%
Dividend- P/FCF- EPS past 5Y48.20% ROI-56.00% 52W High-75.00% Beta1.76
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low28.57% ATR0.06
Employees30 Current Ratio3.30 Sales Q/Q-99.70% Oper. Margin- RSI (14)48.75 Volatility7.57% 13.20%
OptionableNo Debt/Eq0.00 EPS Q/Q-16.40% Profit Margin- Rel Volume0.40 Prev Close0.45
ShortableYes LT Debt/Eq0.00 EarningsNov 21 BMO Payout- Avg Volume330.82K Price0.45
Recom2.00 SMA20-2.51% SMA50-1.77% SMA200-40.71% Volume132,514 Change0.25%
Jun-20-16Initiated ROTH Capital Buy
Jan-08-16Initiated Noble Financial Buy $16
May-26-15Initiated H.C. Wainwright Buy $13
Sep-18-13Initiated Aegis Capital Buy $36
Nov-29-19 05:05AM  HTBX: Third Quarter 2019 Results Zacks Small Cap Research
Nov-20-19 08:00AM  Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients ACCESSWIRE -10.21%
Nov-19-19 07:56AM  The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga +21.84%
Nov-18-19 08:00AM  Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference ACCESSWIRE
Nov-15-19 08:30AM  Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update ACCESSWIRE
Nov-11-19 07:00AM  Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting ACCESSWIRE -8.69%
Nov-08-19 08:14AM  The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga
Nov-07-19 08:02AM  We Think Heat Biologics (NASDAQ:HTBX) Needs To Drive Business Growth Carefully Simply Wall St. -8.18%
Nov-05-19 08:00AM  Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment ACCESSWIRE -13.13%
Oct-24-19 09:00AM  Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting ACCESSWIRE +8.99%
Oct-02-19 09:23AM  What Kind Of Shareholders Own Heat Biologics, Inc. (NASDAQ:HTBX)? Simply Wall St.
Aug-27-19 08:44AM  Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Collapsed 99% Simply Wall St.
Aug-26-19 12:30PM  HTBX: HS-130 Ready To Go Zacks Small Cap Research
Aug-24-19 01:46PM  10 Biopharmaceutical Companies Trying To Cure Cancer Benzinga
Aug-14-19 07:00AM  Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update ACCESSWIRE -6.57%
Aug-12-19 07:00AM  Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heats HS-110 ACCESSWIRE
Aug-07-19 11:15AM  Heat Biologics CEO and Lead Director to Participate in German Investor Forums ACCESSWIRE -7.46%
Jul-10-19 02:41PM  What You Must Know About Heat Biologics, Inc.'s (NASDAQ:HTBX) Beta Value Simply Wall St.
Jul-09-19 08:00AM  Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial ACCESSWIRE
Jun-12-19 01:30PM  HTBX: INDs To Be Filed Soon Zacks Small Cap Research
Jun-03-19 06:55AM  Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure ACCESSWIRE +7.89%
May-23-19 11:09AM  Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers? Simply Wall St. -12.52%
May-20-19 08:30AM  Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference ACCESSWIRE -5.22%
May-15-19 07:30AM  Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update ACCESSWIRE
May-06-19 07:00AM  Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai ACCESSWIRE
Apr-18-19 05:30PM  Heat Biologics CEO to Present at the ThinkEquity Conference in New York City ACCESSWIRE
Apr-11-19 09:30AM  HTBX: 2018 Financial & Operational Results Zacks Small Cap Research
Apr-02-19 08:00AM  Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019 ACCESSWIRE
Mar-28-19 07:30AM  Heat Biologics Reports 2018 Results and Provides Corporate Update ACCESSWIRE
Mar-21-19 07:00AM  Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy ACCESSWIRE
Mar-11-19 10:40AM  HTBX: HS-110 Interim Update Zacks Small Cap Research
Mar-05-19 09:25AM  Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai ACCESSWIRE -6.02%
Feb-28-19 05:00PM  Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium ACCESSWIRE
Feb-26-19 09:45AM  These Four Healthcare Stocks Are Heating Up On Tuesday ACCESSWIRE +17.04%
Feb-13-19 10:03AM  What Type Of Shareholder Owns Heat Biologics, Inc.s (NASDAQ:HTBX)? Simply Wall St.
Jan-14-19 02:15PM  UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial ACCESSWIRE +16.80%
08:00AM  Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial ACCESSWIRE
Jan-10-19 08:27AM  The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits Benzinga
06:30AM  Heat Biologics Provides Clinical and Business Update ACCESSWIRE
Jan-08-19 06:30AM  Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium ACCESSWIRE
Jan-04-19 07:00AM  Heat Biologics to Present at Biotech Showcase 2019 in California ACCESSWIRE
Dec-03-18 10:15AM  HTBX: Plenty of Catalysts in 2019 Zacks Small Cap Research
Nov-27-18 08:38AM  Durham company rakes in another $13.8M through public offering American City Business Journals
Nov-26-18 04:00PM  Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering ACCESSWIRE
06:00AM  Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum ACCESSWIRE
Nov-23-18 08:15AM  Detailed Research: Economic Perspectives on Whirlpool, GrafTech International, Thermon Group, White Mountains Insurance Group, Air Industries Group, and Heat Biologics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-21-18 03:21PM  Heat Biologics Takes Beating After Pricing $12 Million Stock Offering TheStreet.com -30.73%
01:37PM  Should You Be Concerned About Heat Biologics Incs (NASDAQ:HTBX) Historical Volatility? Simply Wall St.
08:04AM  The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO Benzinga
07:30AM  Heat Biologics, Inc. Prices $12,000,000 Public Offering ACCESSWIRE
Nov-20-18 03:10PM  Heat Biologics, Inc. Announces Proposed Public Offering ACCESSWIRE +9.04%
Nov-15-18 07:00AM  Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update ACCESSWIRE +8.55%
Oct-22-18 07:00AM  Heat Biologics to Present at Precision: Lung Cancer World R&D Summit ACCESSWIRE
Oct-19-18 07:00AM  Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City ACCESSWIRE
Oct-10-18 07:00AM  Heat Biologics to Present at the 2018 BIO Investor Forum ACCESSWIRE -5.70%
Oct-04-18 07:00AM  Heat Biologics Pelican Subsidiary Provides Update on its Novel PTX-35 T-Cell Costimulator ACCESSWIRE
Sep-26-18 03:16PM  What does Heat Biologics Incs (NASDAQ:HTBX) Balance Sheet Tell Us About Its Future? Simply Wall St.
Aug-29-18 09:45AM  HTBX: Multiple Milestones on the Horizon Zacks Small Cap Research
07:00AM  Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City ACCESSWIRE
Aug-15-18 04:21PM  Heat Biologics Stock Is a Worthwhile, Speculative Bet InvestorPlace
Aug-14-18 07:30AM  Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update ACCESSWIRE
Jul-30-18 07:00AM  Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
Jul-16-18 09:45AM  HTBX: Heat Biologics: Making an ImPACT on Cancer Zacks Small Cap Research
Jun-29-18 07:10AM  Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-07-18 08:00AM  Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics ACCESSWIRE
Jun-06-18 01:22PM  Is Heat Biologics Inc (NASDAQ:HTBX) Excessively Paying Its CEO? Simply Wall St. +22.13%
May-30-18 07:00AM  Heat Biologics to Present at the 2018 BIO International Convention ACCESSWIRE
May-25-18 07:15AM  Wired News - Clementia Announced Encouraging Phase-2 Part B Data Evaluating Palovarotene for FOP Treatment ACCESSWIRE
May-24-18 07:15AM  Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks ACCESSWIRE +6.80%
May-16-18 08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio Pharmaceuticals ACCESSWIRE +7.69%
May-15-18 07:00AM  Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update ACCESSWIRE +16.55%
May-09-18 06:51AM  Heat Biologics Inc (NASDAQ:HTBX): Risks You Need To Consider Before Buying Simply Wall St.
May-08-18 08:40AM  This Durham company is $20M richer American City Business Journals
May-07-18 05:10PM  Heat Biologics, Inc. Announces Closing of $20.7 Million Public Offering ACCESSWIRE
May-03-18 08:30AM  Heat Biologics, Inc. Prices $18,000,000 Public Offering ACCESSWIRE -48.59%
May-01-18 08:24AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +94.86%
08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics and Immunomedics ACCESSWIRE
Apr-23-18 02:57PM  Heat Bio looks to milestones, $15.5M from offering American City Business Journals
Apr-18-18 07:00AM  Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110 ACCESSWIRE
Apr-10-18 10:39AM  Who Are Heat Biologics Incs (NASDAQ:HTBX) Major Shareholders? Simply Wall St.
Mar-26-18 07:00AM  Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform ACCESSWIRE
Mar-20-18 11:57AM  On heels of adopting 'poison pill', Heat Bio recruits new scientific expertise American City Business Journals
Mar-19-18 06:00AM  Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards ACCESSWIRE -10.24%
Mar-14-18 07:00AM  Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium ACCESSWIRE +7.77%
Mar-13-18 07:00AM  Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam ACCESSWIRE
Mar-12-18 08:00AM  Heat Biologics Adopts Stockholder Rights Plan ACCESSWIRE
Mar-08-18 02:59PM  Has Heat Biologics Inc (NASDAQ:HTBX) Improved Earnings Growth In Recent Times? Simply Wall St. -6.54%
Mar-02-18 05:00PM  Heat Biologics Reports Fiscal Year 2017 Financial Results ACCESSWIRE
Feb-28-18 06:00AM  Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC) ACCESSWIRE -6.67%
Feb-26-18 07:00AM  UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study ACCESSWIRE +11.13%
Feb-20-18 01:00PM  Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer ACCESSWIRE
Feb-14-18 07:00AM  Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond ACCESSWIRE +5.81%
Feb-07-18 07:05AM  Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York ACCESSWIRE
Feb-01-18 08:20AM  Todays Research Reports on Trending Tickers: Heat Biologics and ImmunoGen ACCESSWIRE
Jan-30-18 07:00AM  Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study ACCESSWIRE +8.43%
Jan-22-18 05:55PM  Heat latest Triangle biopharma to execute reverse stock split American City Business Journals -6.47%
Jan-02-18 08:39PM  Should You Be Concerned About Heat Biologics Incs (NASDAQ:HTBX) Investors? Simply Wall St.
Dec-11-17 01:58PM  ETFs with exposure to Heat Biologics, Inc. : December 11, 2017 Capital Cube -7.82%
Dec-07-17 07:00AM  Heat Biologics Receives FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Cell Lung Cancer ACCESSWIRE
Nov-30-17 01:58PM  ETFs with exposure to Heat Biologics, Inc. : November 30, 2017 Capital Cube
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therap, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. Its preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. The company was founded in 2008 and is headquartered in Durham, North Carolina.